

Brenda Grossman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3113999/publications.pdf>

Version: 2024-02-01

59
papers

4,378
citations

279487

23
h-index

205818

48
g-index

60
all docs

60
docs citations

60
times ranked

6761
citing authors

#	ARTICLE	IF	CITATIONS
1	Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*. Annals of Internal Medicine, 2012, 157, 49.	2.0	920
2	Clinical Practice Guidelines From the AABB. JAMA - Journal of the American Medical Association, 2016, 316, 2025.	3.8	871
3	Platelet Transfusion: A Clinical Practice Guideline From the AABB. Annals of Internal Medicine, 2015, 162, 205-213.	2.0	717
4	Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation, 2020, 130, 2757-2765.	3.9	649
5	Platelet transfusion: a systematic review of the clinical evidence. Transfusion, 2015, 55, 1116-1127.	0.8	131
6	The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2021, 96, 1262-1275.	1.4	129
7	A national survey of transfusion-related acute lung injury risk reduction policies for platelets and plasma in the United States. Transfusion, 2010, 50, 1312-1321.	0.8	59
8	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Frontiers in Medicine, 2021, 8, 684151.	1.2	50
9	Efficacy of extracorporeal photopheresis in clearance of antibodies to donor-specific and lung-specific antigens in lung transplant recipients. Journal of Heart and Lung Transplantation, 2014, 33, 950-956.	0.3	49
10	Red Cell Transfusion Decreases Hemoglobin A1c in Patients with Diabetes. Clinical Chemistry, 2011, 57, 344-346.	1.5	46
11	Transfusion-related acute lung injury risk mitigation: an update. Vox Sanguinis, 2017, 112, 694-703.	0.7	44
12	Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Medicine, 2021, 18, e1003872.	3.9	43
13	Multiple False Reactionse in Viral Antibody Screening Assays after Influenza Vaccination. American Journal of Epidemiology, 1995, 141, 1089-1096.	1.6	40
14	<scp>COVID</scp>-19 convalescent plasma: Interim recommendations from the <scp>AABB</scp>. Transfusion, 2021, 61, 1313-1323.	0.8	40
15	Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1072-1077.	2.0	39
16	Barriers and motivators to blood and cord blood donations in young African-American women. American Journal of Hematology, 2005, 78, 198-202.	2.0	37
17	AABB Committee Report: reducing transfusion-transmitted cytomegalovirus infections. Transfusion, 2016, 56, 1581-1587.	0.8	33
18	Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study. Transfusion, 2017, 57, 1522-1526.	0.8	30

#	ARTICLE	IF	CITATIONS
19	Increased risk of a positive test for antibody to hepatitis B core antigen (anti-HBC) in autologous blood donors. <i>Transfusion</i> , 1988, 28, 283-285.	0.8	29
20	Reducing the risk of transfusion-transmitted cytomegalovirus infection: a systematic review and meta-analysis. <i>Transfusion</i> , 2016, 56, 1569-1580.	0.8	29
21	Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. <i>Journal of Clinical Apheresis</i> , 2017, 32, 215-223.	0.7	27
22	The B antigen protects against the development of red meat allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1790-1791.e3.	2.0	25
23	Familial Haploidentical Stem Cell Transplant in Children and Adolescents With High-Risk Sickle Cell Disease. <i>JAMA Pediatrics</i> , 2020, 174, 195.	3.3	25
24	Linear relationship between lymphocyte counts in peripheral blood and buffy coat collected during extracorporeal photopheresis. <i>Transfusion</i> , 2013, 53, 2635-2643.	0.8	24
25	ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. <i>Vox Sanguinis</i> , 2021, 116, 766-773.	0.7	22
26	TRANSFUSION PRACTICE: Liver donor's age and recipient's serum creatinine predict blood component use during liver transplantation. <i>Transfusion</i> , 2009, 49, 2645-2651.	0.8	21
27	Red blood cell transfusion for hematologic disorders. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 454-461.	0.9	20
28	Platelet transfusion in thrombotic thrombocytopenic purpura. <i>Vox Sanguinis</i> , 2015, 109, 168-172.	0.7	19
29	Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2065-2069.	2.0	19
30	Antibody of undetermined specificity: frequency, laboratory features, and natural history. <i>Transfusion</i> , 2013, 53, 931-938.	0.8	18
31	The Assessment of Convalescent Plasma Efficacy against COVID-19. <i>Med</i> , 2020, 1, 66-77.	2.2	17
32	Thrombotic Thrombocytopenic Purpura and Graves Disease. <i>American Journal of the Medical Sciences</i> , 2007, 334, 133-135.	0.4	14
33	Blood Transfusion-Acquired Hemoglobin C. <i>Archives of Pathology and Laboratory Medicine</i> , 1999, 123, 642-643.	1.2	12
34	Platelet recovery rate during plasma exchange predicts early and late responses in patients with thrombotic thrombocytopenic purpura (TTP). <i>Transfusion</i> , 2013, 53, 1096-1107.	0.8	9
35	Using direct antiglobulin test results to reduce unnecessary cold agglutinin testing. <i>Transfusion</i> , 2017, 57, 1480-1484.	0.8	9
36	Sterility testing of apheresis hematopoietic progenitor cell products using an automated blood culture system. <i>Transfusion</i> , 2013, 53, 2659-2666.	0.8	8

#	ARTICLE	IF	CITATIONS
37	High Resolution HLA Typing by Next Generation Exome Sequencing. <i>Blood</i> , 2012, 120, 4166-4166.	0.6	7
38	Safety and collection efficiency with a lower transfusion threshold for extracorporeal photopheresis in adult patients with graft-versus-host disease. <i>Vox Sanguinis</i> , 2017, 112, 379-387.	0.7	6
39	Transfusion requirements and 30-day mortality predictors for adult hemophagocytic lymphohistiocytosis. <i>International Journal of Hematology</i> , 2018, 108, 485-490.	0.7	6
40	WHO covid-19 drugs guideline: reconsider using convalescent plasma. <i>BMJ, The</i> , 2022, 376, o295.	3.0	6
41	A quantitative model to predict blood use in adult orthotopic liver transplantation. <i>Transfusion and Apheresis Science</i> , 2015, 53, 386-392.	0.5	5
42	The efficacy of extracorporeal photopheresis to arrest bronchiolitis obliterans in lung allograft recipients was compared between two automated photopheresis instruments. <i>Transfusion</i> , 2018, 58, 2933-2941.	0.8	5
43	A retrospective review of the outcome of plasma exchange and aggressive medical therapy in antibody mediated rejection of renal allografts: A single center experience. <i>Journal of Clinical Apheresis</i> , 2008, 23, 178-182.	0.7	4
44	Autologous blood: A greater risk for the homologous recipient. <i>Transfusion Science</i> , 1989, 10, 125-130.	0.6	3
45	Rh(D) alloimmunization without apparent exposure to Rh(D) antigen. <i>American Journal of Hematology</i> , 2006, 81, 218-218.	2.0	3
46	Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359). <i>Blood</i> , 2014, 124, 2582-2582.	0.6	3
47	What is Your Guess? A Donor Going Green. <i>Clinical Chemistry</i> , 2010, 56, 1905-1906.	1.5	2
48	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
49	Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing CD34 Enrichment and Mononuclear (CD3) Addback in High Risk Patients with Sickle Cell Disease (SCD). <i>Blood</i> , 2018, 132, 162-162.	0.6	1
50	Commentary. <i>Clinical Chemistry</i> , 2012, 58, 1290-1290.	1.5	0
51	The CELLEX is comparable to the UVARâ€XTS for the treatment of acute and chronic graft versus host disease (GVHD). <i>Transfusion</i> , 2020, 60, 351-357.	0.8	0
52	Initial Platelet Recovery Rate During Plasma Exchange Predicts Long-Term Survival in Patients with Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2011, 118, 3283-3283.	0.6	0
53	Linear Relationship Between Lymphocyte Counts in Peripheral Blood and Buffy Coat During Extracorporeal Photopheresis in Patients with Graft-Versus-Host Disease. <i>Blood</i> , 2012, 120, 4171-4171.	0.6	0
54	Effect of Lower Hematocrits on Buffy Coat Collection during Extracorporeal Photopheresis in Patients with Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 1145-1145.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Comparison of Outcomes between the Cellex and Uvar-Xts Closed-System Extracorporeal Photopheresis (ECP) Devices When Used for Graft-Versus-Host Disease; A Single Center Experience. Blood, 2018, 132, 4686-4686.	0.6	0
56	Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359). Blood, 2019, 134, 1990-1990.	0.6	0
57	Improving Transfusion Practices Through Patient Blood Management Programs. Mayo Clinic Proceedings, 2021, 96, 2936-2938.	1.4	0
58	Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359). Blood, 2020, 136, 20-21.	0.6	0
59	Transfusion-related HIV infection. Journal of the Medical Association of Georgia, 1988, 77, 165-7.	0.1	0